What Is the Relevance of Antimicrobial Resistance on the Outcome of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae? (Should Macrolide Monotherapy Be Used for Mild Pneumonia?)

被引:14
|
作者
Low, Donald E. [1 ,2 ]
机构
[1] Univ Hlth Network, Dept Microbiol, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Toronto, ON M5G 1X5, Canada
关键词
Community-acquired pneumonia; Streptococcus pneumoniae; Antimicrobial resistance; Resistance paradox; Pollyanna phenomenon; Macrolides; beta-lactams; Fluoroquinolones; IN-VITRO RESISTANCE; PNEUMOCOCCAL PNEUMONIA; MYCOPLASMA-PNEUMONIAE; PENICILLIN RESISTANCE; INFECTIOUS-DISEASES; SUSCEPTIBILITY; BACTEREMIA; MORTALITY; SOCIETY; ADULTS;
D O I
10.1016/j.idc.2012.11.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multidrug-resistant pneumococci continue to increase worldwide. Although there are still questions regarding the relevance of beta-lactam resistance, the recommendation for the use of the macrolides as monotherapy for mild community-acquired pneumonia should be revisited in view of high rates of resistance, the association of clinical failures with low-level and high-level resistance, and the lack of clinical data to support their need for empirical therapy for the atypicals.
引用
收藏
页码:87 / +
页数:12
相关论文
共 50 条
  • [1] Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia
    Lynch, JP
    Martinez, FJ
    CLINICAL INFECTIOUS DISEASES, 2002, 34 : S27 - S46
  • [2] Antimicrobial resistance in Streptococcus pneumoniae:: Implications for patients with community-acquired pneumonia
    Chenoweth, CE
    Saint, S
    Martinez, F
    Lynch, JP
    Fendrick, AM
    MAYO CLINIC PROCEEDINGS, 2000, 75 (11) : 1161 - 1168
  • [3] Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae
    Jones, RN
    Andes, DR
    Mandell, LA
    Gothelf, S
    Ehrhardt, AF
    Nicholson, SC
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (01) : 93 - 100
  • [4] Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae
    Isozumi, Rie
    Yoshimine, Hiroyuki
    Morozumi, Miyuki
    Ubukata, Kimiko
    Ariyoshi, Koya
    RESPIROLOGY, 2009, 14 (08) : 1206 - 1208
  • [5] The clinical significance of Streptococcus pneumoniae resistance in community-acquired pneumonia
    Manika, Katerina
    Kioumis, Ioannis
    PNEUMON, 2011, 24 (04) : 379 - 391
  • [6] The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae
    Yayan, Josef
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1733 - 1743
  • [7] The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia
    Feldman, Charles
    Anderson, Ronald
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (06) : 806 - 818
  • [8] Community-acquired Pneumonia Caused by Macrolide-resistant Mycoplasma pneumoniae in Adults
    Hanada, Shigeo
    Morozumi, Miyuki
    Takahashi, Yui
    Mochizuki, Sayaka
    Sato, Toshitaka
    Suzuki, Shinko
    Uruga, Hironori
    Takaya, Hisashi
    Miyamoto, Atsushi
    Morokawa, Nasa
    Ubukata, Kimiko
    Kishi, Kazuma
    INTERNAL MEDICINE, 2014, 53 (15) : 1675 - 1678
  • [9] Streptococcus pneumoniae in community-acquired pneumonia -: How important is drug resistance?
    Bauer, T
    Ewig, S
    Marcos, MA
    Schultze-Werninghaus, G
    Torres, A
    MEDICAL CLINICS OF NORTH AMERICA, 2001, 85 (06) : 1367 - +
  • [10] Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia
    Morozumi, Miyuki
    Iwata, Satoshi
    Hasegawa, Keiko
    Chiba, Naoko
    Takayanagi, Reiko
    Matsubara, Keita
    Nakayama, Eiichi
    Sunakawa, Keisuke
    Ubukata, Kimiko
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) : 348 - 350